|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
To identify a metabolic inhibitor for EVI1-induced metabolic reprogramming in MLL-r AML, we used an XFp extracellular flux analyzer to examine metabolic changes during leukemia development in mouse models of AML expressing MLL-AF9 and Evi1 (Evi1/MF9).
|
31649131 |
2019 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Leukemia fusion gene analysis demonstrated positive EVI1 and negative IgH and TCR gene rearrangement.
|
30608452 |
2019 |
|
leukemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
However, aberrantly high expression of EVI1 has potent oncogenic properties and confers poor prognosis and chemo-resistance in leukemia and solid tumors.
|
29939287 |
2018 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
We demonstrate for the first time that EVI1 acts as a regulator of its own expression, highlighting the complex regulation of EVI1, and open new directions to better understand the mechanisms of EVI1 overexpressing leukemias.
|
28391050 |
2017 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Genetic deletion of CXCR4 in murine hematopoietic progenitors abrogated leukemogenesis induced by constitutively active Notch1, whereas lack of CCR6 and CCR7, which have been shown to be involved in T cell and leukemia extravasation into the central nervous system, respectively, did not influence T cell acute lymphoblastic leukemia development.
|
26931577 |
2016 |
|
leukemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
High EVI1 expression was detected mainly in myelomonocytic-lineage (designated as e-M4/M5 subtype) leukemia with MLL rearrangements and in megakaryocytic-lineage (designated as e-M7 subtype) leukemia, and its prognostic association was observed in the e-M4/M5 subtype but not in the e-M7 subtype.
|
25567132 |
2015 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
VPA may be a promising choice in the molecular targeting therapy of RUNX1-Evi-1-related leukemia.
|
26674644 |
2015 |
|
leukemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
These results establish the mechanistic basis underlying the pathogenesis of a severe form of leukemia through aberrant expression of the EVI1 proto-oncogene.
|
24703906 |
2014 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
A single oncogenic enhancer rearrangement causes concomitant EVI1 and GATA2 deregulation in leukemia.
|
24703711 |
2014 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Genomic dark matter sheds light on EVI1-driven leukemia.
|
24735919 |
2014 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
This study opens new directions to further understand the mechanisms of EVI1 overexpressing leukemias.
|
22689058 |
2013 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
These findings provide a foundation for future study of potential therapeutic gene targets for EVI1-induced leukemia.
|
23826213 |
2013 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
This mirrored a difference seen in 5'-mC between MLL-rearranged human leukemias that are either EVI1 positive or EVI1 negative.
|
23235717 |
2013 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Using the Evi1(pos) MLL-AF9 mouse leukemia model, we demonstrate increased sensitivity to chemotherapeutic agents on reduction of Evi1 expression.
|
22553314 |
2012 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
The PTEN/AKT/mTOR signaling pathway and the Evi1-polycomb interaction can be promising therapeutic targets for leukemia with activated Evi1.
|
21289308 |
2011 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here, we review the current understanding of the role of Evi1 in controlling the development of leukemia and highlight potential modalities for targeting factors involved in Evi1-regulated signaling.
|
21795762 |
2011 |
|
leukemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
As EVI1 overexpression alone is not sufficient to induce leukemia, loss of a 7q tumour suppressor gene might be a required cooperating event.
|
20084277 |
2010 |
|
leukemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Overexpression of EVI-1 also occurs with high frequency in leukemia patients without 3q26 abnormalities, and importantly, high EVI-1 expression is an independent negative prognostic indicator irrespective of the presence of 3q26 rearrangements.
|
19385966 |
2009 |
|
leukemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Histone deacetyltransferase could be a target in molecular therapy of RUNX1-EVI1-expressing leukemia.
|
19016745 |
2008 |
|
leukemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
These results suggest that EVI1 overexpression was the major factor contributing to leukemogenesis, and the late appearance of the Ph chromosome is closely associated with the progression to an aggressive form of leukemia.
|
18206536 |
2008 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
The functions of EVI1/MEL1 members as transcription factors and the concept of EVI1-positive leukemia as a stem cell disease are also reviewed.
|
17483069 |
2007 |
|
leukemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Experimental overexpression of EVI1 by itself was insufficient to cause leukemia in animal model systems, but it cooperated with other genes in this process.
|
17507183 |
2007 |
|
leukemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The EVI1 transcriptional repressor is critical to the normal development of a variety of tissues and participates in the progression of acute myeloid leukaemias.
|
17635584 |
2007 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our results underscore the feasibility of FISH as an adjunct to PCR for the identification of EVI1 deranged leukemias and identified EVI1 as the principal transcript expressed in these malignancies.
|
16342172 |
2006 |
|
leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Integrations are located in intron 1 or 2, where they promote expression of truncated proteins lacking the PRDI-BF1-RIZ1 homologous (PR) domain, similar to what is observed in human leukemias with EVI1 or PRDM16 mutations.
|
16109773 |
2005 |